CLIFF
Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. The company operates through two segments, Banking and Diagnostics. It provides cord blood, cord lining, and cord tissue banking services comprising processing and storage of stem cells; and non-invasive prenatal testing, paediatric vision screening, newborn metabolic screening, and newborn genetic screening services. The company also offers preimplantation genetic screening, endometrial receptivity test, paediatric allergen test, and genetic talent test services, as well as moms up, a mobile app for pregnancy and parenting resources. In addition, it provides management, marketing, and property investment services. Cordlife Group Limited was incorporated in 2001 and is headquartered in Singapore.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.01 | $9M | -$1M |
| 2025 Q4 | -0.02 | $9M | -$803,399 |
| 2025 Q3 | -0.01 | $10M | — |
| 2025 Q2 | -0.01 | $10M | -$1M |
| 2025 Q1 | -0.01 | $10M | -$1M |
| 2024 Q4 | -0.01 | $9M | -$4M |
| 2024 Q3 | -0.01 | $9M | -$4M |
| 2024 Q2 | -0.02 | $5M | -$4M |